Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition.

RAF/MEK glue compounds enable full-dose pan-RAF inhibitor therapy by spatially modulating RAF, achieving potent tumor suppression in RAS-mutant models.

• Why it matters: Overcoming toxicity limits in MAPK pathway inhibition is crucial for effective RAS-mutant cancer treatments, as current combinations are hampered by feedback mechanisms and side effects.
• What they did: The study used RAF/MEK glue molecules to stabilize RAF-MEK complexes, trapping RAF in the cytosol and preventing activation, allowing full-dose pan-RAF inhibitor use in tumor models.
• The result: This approach led to significant tumor regressions, including in resistant models, highlighting a promising strategy for selective, potent RAS-mutant cancer therapies.